You are here: Industry Insights > Pharma in China

Pharma in China

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
New Pathways for Innovation and Transformation of Local Pharmaceutical Companies Xiaobin
December 20, 2024
INNOVATION announced it will acquire 100% equity in CSPC Baike for up to RMB 7.6 billion, 10% in cash and 90% in shares.
Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field xiaobin
December 20, 2024
Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.
Buyers and Sellers in the Weight Loss M&A Market：Without Buying and Selling, There's No Reshuffle Krebs Qin
December 20, 2024
The development of weight-loss drugs is currently one of the hottest topics in the pharmaceutical industry.
Universal CAR-T, Transaction +1 xiaobin
December 20, 2024
CAR-T therapy (chimeric antigen receptor t-cell immunotherapy) has been a favorite of the innovative drug market in recent years.
Popular APIs of the Year at Pharmasources.com PharmaSources
December 10, 2024
What are the APIs that caught the highest attention in the year at PharmaSources.com？
Has the Booming PD-1 Inhibitor Reached its Limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology Krebs Qin
October 18, 2024
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca? wan
October 18, 2024
On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
Where Lies the Competitiveness of China's New Drugs for Central Nervous System? Prof. Zhang
October 18, 2024
The Global Challenges and Opportunities of the R&D of New Drugs for Central Nervous System